Work

A combined phase I/II study of a novel bicycle tumor-targeted immune cell agonist BT7480 in patients with nectin-4 associated advanced malignancies.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.tps2689

Authors: Kyriakos P. Papadopoulos, Afshin Dowlati, Amy Dickson, Sandra Hirschberg, Sally Westrup, Punit Upadhyaya, Heather Cohen, Kristen Hurov, Roshawn Watson, Sebastien Hazard, Dominic Smethurst, Jordi Rodon Ahnert

Institutions: South Texas Accelerated Research Therapeutics, University Hospitals Cleveland Medical Center, Bicycle Therapeutics (United Kingdom), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4286294090

Cites:

Cited by: 2

Related to: 10